Loading...
XNAS
BIIB
Market cap19bUSD
Jul 10, Last price  
135.33USD
1D
1.74%
1Q
17.50%
Jan 2017
-52.28%
Name

Biogen Inc

Chart & Performance

D1W1MN
P/E
12.15
P/S
2.05
EPS
11.14
Div Yield, %
—
Shrs. gr., 5y
-4.88%
Rev. gr., 5y
-7.62%
Revenues
9.68b
-1.62%
1,713,619,0001,872,185,0003,171,617,0004,097,507,0004,377,348,0004,716,423,0005,048,634,0005,516,461,0006,932,199,0009,703,324,00010,763,800,00011,448,800,00012,273,900,00013,452,900,00014,377,900,00013,444,600,00010,981,700,00010,173,400,0009,835,600,0009,675,900,000
Net income
1.63b
+40.57%
160,711,000217,511,000638,172,000783,167,000970,132,0001,005,273,0001,234,428,0001,380,033,0001,862,341,0002,934,784,0003,547,000,0003,702,800,0002,539,100,0004,430,700,0005,888,500,0004,000,600,0001,556,100,0003,046,900,0001,161,100,0001,632,200,000
CFO
2.88b
+85.85%
889,503,000841,268,0001,020,635,0001,564,492,0001,074,898,0001,624,673,0001,727,741,0001,879,897,0002,345,078,0002,942,115,0003,716,100,0004,522,400,0004,551,000,0006,187,700,0007,078,600,0004,229,800,0003,639,900,0001,384,300,0001,547,200,0002,875,500,000
Earnings
Jul 30, 2025

Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
URL
https://www.biogen.com/
IPO date
Sep 17, 1991
Employees
8,725
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
9,675,900
-1.62%
9,835,600
-3.32%
10,173,400
-7.36%
Cost of revenue
2,041,800
7,497,700
6,913,000
Unusual Expense (Income)
NOPBT
7,634,100
2,337,900
3,260,400
NOPBT Margin
78.90%
23.77%
32.05%
Operating Taxes
273,800
135,300
632,800
Tax Rate
3.59%
5.79%
19.41%
NOPAT
7,360,300
2,202,600
2,627,600
Net income
1,632,200
40.57%
1,161,100
-61.89%
3,046,900
95.80%
Dividends
Dividend yield
Proceeds from repurchase of equity
(44,300)
(751,900)
BB yield
0.12%
1.86%
Debt
Debt current
1,748,600
240,300
97,200
Long-term debt
5,216,200
7,588,200
6,947,000
Deferred revenue
Other long-term liabilities
732,300
781,100
944,200
Net debt
4,029,300
6,317,900
(83,500)
Cash flow
Cash from operating activities
2,875,500
1,547,200
1,384,300
CAPEX
(153,700)
277,000
(243,200)
Cash from investing activities
(799,200)
(4,101,000)
1,576,600
Cash from financing activities
(683,500)
149,300
(1,759,700)
FCF
8,575,200
1,025,400
1,749,000
Balance
Cash
2,375,000
1,049,900
4,892,800
Long term investments
560,500
460,700
2,234,900
Excess cash
2,451,705
1,018,820
6,619,030
Stockholders' equity
19,123,700
17,474,000
16,292,200
Invested Capital
21,626,895
21,990,180
14,164,870
ROIC
33.75%
12.18%
18.91%
ROCE
31.46%
9.89%
15.44%
EV
Common stock shares outstanding
145,900
145,600
146,000
Price
152.92
-40.91%
258.77
-6.55%
276.92
15.42%
Market cap
22,311,028
-40.78%
37,676,912
-6.81%
40,430,320
12.64%
EV
26,340,328
43,994,812
40,337,320
EBITDA
8,307,300
2,832,700
3,778,800
EV/EBITDA
3.17
15.53
10.67
Interest
246,900
246,600
Interest/NOPBT
10.56%
7.56%